Catalyze supported TetraKit in preparing our successful submission to the EIC Accelerator (October 2024 round). We were awarded blended financing to advance the clinical development of our lead asset, ¹³¹I-DualFAPi. Initially focused on metastasized Triple Negative Breast Cancer, this therapy has the potential to benefit a broad population of cancer patients worldwide.
Full article by Catalyze can be viewd here: https://www.linkedin.com/feed/update/urn:li:activity:7361661664997322752
